Douglas Milikien

Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial)

Gregory S. Thomas, Bruce R. Tammelin, George L. Schiffman et al. · Journal of Nuclear Cardiology · 2008 · 120 citations

Medicine, Pharmacology, Pharmacotherapy +12

The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging

Gregory S. Thomas, Randall C. Thompson, Michael I. Miyamoto et al. · Journal of Nuclear Cardiology · 2009 · 92 citations

Medicine, Cardiology, Pharmacology +17

Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder

Brendan Lee, George A. Díaz, William J. Rhead et al. · Genetics in Medicine · 2014 · 42 citations · Full text

Life Sciences, Nephrology, Renal Pathophysiology +2

Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio

Masoud Mokhtarani, George A. Díaz, William J. Rhead et al. · Molecular Genetics and Metabolism · 2013 · 38 citations · Full text

Life Sciences, Pharmacology, Hepatic Pharmacotherapy +5